Tetragenetics (AbCellera) is at the forefront of developing innovative antibody medicines, focusing on creating first-in-class and best-in-class therapies. The company employs advanced antibody discovery and development technologies that enable the identification of high-value drug classes and targets. Notably, they are pioneering the development of T-cell engagers (TCEs) aimed at enhancing cancer treatment efficacy while minimizing safety concerns. Their approach includes generating TCEs that effectively kill tumor cells without causing excessive cytokine release, addressing a significant barrier in solid tumor therapies. This innovative strategy positions Tetragenetics as a leader in the field of immuno-oncology.

In addition to T-cell engagers, Tetragenetics is also exploring the development of antibodies targeting transmembrane proteins and G-protein coupled receptors (GPCRs) for various medical conditions, including metabolic disorders, pain management, and autoimmunity. Their commitment to advancing science is reflected in their collaborative efforts with major pharmaceutical partners and their internal pipeline of programs. By leveraging cutting-edge technologies and a dedicated team of scientists and professionals, Tetragenetics aims to push the boundaries of antibody therapy and improve patient outcomes across a range of diseases.

United States

TetraGenetics harnesses the unique capabilities of the protozoa Tetrahymena thermophila to produce recombinant proteins for use in the discovery of novel antibody therapeutics targeting membrane proteins implicated in numerous human diseases.

Tetragenetics(AbCellera)

Company Details